Matt Zeller, Novartis country president for Australia and New Zealand, said, “We welcome the PBS listing of KISQALI for node-positive patients at high risk of cancer recurrence. Importantly, this milestone provides the EBC community with more treatment choices, but we recognise there is still more work to be done." …
New treatment option for early breast cancer at high risk of recurrence
July 2, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News